Abstract

ObjectivesChronic hepatitis C (CHC) infection affects more than 70 million people worldwide and imposes considerable health and economic burdens on patients and society. This study estimated 2 understudied components of the economic burden, patient out-of-pocket (OOP) costs and time costs, in patients with CHC in a tertiary hospital clinic setting and a community clinic setting. MethodsThis was a multicenter, cross-sectional study with hospital-based (n = 174) and community-based (n = 101) cohorts. We used a standardized instrument to collect healthcare resource use, time, and OOP costs. OOP costs included patient-borne costs for medical services, nonprescription drugs, and nonmedical expenses related to healthcare visits. Patient and caregiver time costs were estimated using an hourly wage value derived from patient-reported employment income and, where missing, derived from the Canadian census. Sensitivity analysis explored alternative methods of valuing time. Costs were reported in 2020 Canadian dollars. ResultsThe mean 3-month OOP cost was $55 (95% confidence interval [CI] $21-$89) and $299 (95% CI $170-$427) for the community and hospital cohorts, respectively. The mean 3-month patient time cost was $743 (95% CI $485-$1002) (community) and $465 (95% CI $248-$682) (hospital). The mean 3-month caregiver time cost was $31 (95% CI $0-$63) (community) and $277 (95% CI $174-$380) (hospital). Patients with decompensated cirrhosis bore the highest costs. ConclusionsOOP costs and patient and caregiver time costs represent a considerable economic burden to patient with CHC, equivalent to 14% and 21% of the reported total 3-month income for the hospital-based and community-based cohorts, respectively.

Highlights

  • Hepatitis C virus (HCV) affects more than 70 million people worldwide[1,2] and imposes a substantial health burden.[3]

  • 275 participants were included in the analyses, 101 (37%) from community clinics and 174 (63%) from the hospital clinics (Table 1)

  • decompensated cirrhosis (DC) and natural log income were significantly associated with caregiver time cost

Read more

Summary

Introduction

Hepatitis C virus (HCV) affects more than 70 million people worldwide[1,2] and imposes a substantial health burden.[3] Approximately 15% to 45% of those infected clear the infection spontaneously. The remainder progress to chronic infection.[4,5] As many as 40% progress asymptomatically to cirrhosis and hepatocellular carcinoma (HCC), with an increased risk of premature death.[6,7,8] treatment for chronic hepatitis C (CHC) changed significantly with the advent of interferon-free direct-acting antiviral agents (DAAs) in 2014. Research has shown that DAAs are highly cost-effective.[10,11,12,13,14,15,16,17] DAAs have been approved and covered in many jurisdictions worldwide for treating patients with CHC

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.